# Glycolysis enzymes and cellular lactylation in tumour

**Authors:** Chenyuan Dai, Lihua Wang

PMC · DOI: 10.1002/ctm2.70549 · Clinical and Translational Medicine · 2026-02-18

## TL;DR

This paper reviews how glycolysis enzymes affect lactylation in cancer cells, influencing tumor growth and suggesting lactylation as a potential cancer therapy target.

## Contribution

The paper provides a comprehensive review of the role of glycolytic enzymes in regulating lactylation and its implications for tumor biology.

## Key findings

- Glycolytic enzymes modulate lactylation in cancer cells.
- Lactylation promotes tumor growth, metastasis, and immune evasion.
- Targeting lactylation is a promising strategy for cancer therapy.

## Abstract

Cellular lactylation, a recently identified post‐translational modification, has emerged as a crucial regulator in various biological processes, particularly in cancer. The discovery of lactylation provides a new perspective for understanding the functional significance of the Warburg effect in tumour cells. Enzymes involved in the glycolytic pathway modulate lactylation, influencing tumour genesis and progression. This review explores the intricate relationship between glycolysis, lactylation and tumour biology, with a focus on how enzymes participating in glycolysis impact lactylation in cancer cells. We discuss how glycolytic enzymes regulate lactylation and highlight their broader implications in tumour biology. The role of lactylation in shaping the tumour microenvironment underscores its increasing significance as a biomarker for cancer prognosis and a target for therapeutic intervention. Therefore, we also summarised the potential of targeting lactylation as a cancer therapy strategy.

Glycolytic enzymes regulate lactylation in cancer cells.Lactylation drives tumour growth, metastasis, immune evasion and contributes to microenvironment remodellingTargeting lactylation holds promise for cancer therapy.

Glycolytic enzymes regulate lactylation in cancer cells.

Lactylation drives tumour growth, metastasis, immune evasion and contributes to microenvironment remodelling

Targeting lactylation holds promise for cancer therapy.

Graphical Headlights

• Glycolytic enzymes regulate lactylation in cancer cells.

• Lactylation drives tumour growth, metastasis, immune evasion and contributes to microenvironment remodelling.

• Targeting lactylation holds promise for cancer therapy.

## Linked entities

- **Diseases:** cancer (MONDO:0004992)

## Full-text entities

- **Genes:** SLC16A3 (solute carrier family 16 member 3) [NCBI Gene 9123] {aka MCT 3, MCT 4, MCT-3, MCT-4, MCT3, MCT4}, ACSS2 (acyl-CoA synthetase short chain family member 2) [NCBI Gene 55902] {aka ACAS2, ACECS, ACS, ACSA, AceCS1, dJ1161H23.1}, PKM (pyruvate kinase M1/2) [NCBI Gene 5315] {aka CTHBP, HEL-S-30, OIP3, PK3, PKM2, TCB}, CTNNB1 (catenin beta 1) [NCBI Gene 1499] {aka CTNNB, EVR7, MRD19, NEDSDV, armadillo}, METTL3 (methyltransferase 3, N6-adenosine-methyltransferase complex catalytic subunit) [NCBI Gene 56339] {aka IME4, M6A, MT-A70, Spo8, hMETTL3}, BACH1 (BTB domain and CNC homolog 1) [NCBI Gene 571] {aka BACH-1, BTBD24}, NFE2L2 (NFE2 like bZIP transcription factor 2) [NCBI Gene 4780] {aka IMDDHH, NRF2, Nrf-2}, MCM7 (minichromosome maintenance complex component 7) [NCBI Gene 4176] {aka CDC47, MCM2, P1.1-MCM3, P1CDC47, P85MCM, PNAS146}, TGFB1 (transforming growth factor beta 1) [NCBI Gene 7040] {aka CAEND1, CED, DPD1, IBDIMDE, LAP, TGF-beta1}, PFKM (phosphofructokinase, muscle) [NCBI Gene 5213] {aka ATP-PFK, GSD7, PFK-1, PFK-A, PFK1, PFKA}, EP300 (EP300 lysine acetyltransferase) [NCBI Gene 2033] {aka KAT3B, MKHK2, RSTS2, p300}, FBP [NCBI Gene 8056], S100A4 (S100 calcium binding protein A4) [NCBI Gene 6275] {aka 18A2, 42A, CAPL, FSP1, MTS1, P9KA}, NOP2 (NOP2 nucleolar protein) [NCBI Gene 4839] {aka NOL1, NOP120, NSUN1, p120}, CCL2 (C-C motif chemokine ligand 2) [NCBI Gene 6347] {aka GDCF-2, HC11, HSMCR30, MCAF, MCP-1, MCP1}, CD8A (CD8 subunit alpha) [NCBI Gene 925] {aka CD8, CD8alpha, IMD116, Leu2, p32}, HDAC9 (histone deacetylase 9) [NCBI Gene 9734] {aka HD7, HD7b, HD9, HDAC, HDAC7B, HDAC9B}, MSN (moesin) [NCBI Gene 4478] {aka HEL70, IMD50}, LRRC15 (leucine rich repeat containing 15) [NCBI Gene 131578] {aka LIB}, RUBCNL (rubicon like autophagy enhancer) [NCBI Gene 80183] {aka C13orf18, KIAA0226L, PACER}, PDK4 (pyruvate dehydrogenase kinase 4) [NCBI Gene 5166], CNOT6 (CCR4-NOT transcription complex subunit 6) [NCBI Gene 57472] {aka CCR4, Ccr4a}, PDGFRB (platelet derived growth factor receptor beta) [NCBI Gene 5159] {aka CD140B, IBGC4, IMF1, JTK12, KOGS, OPDKD}, PFKP (phosphofructokinase, platelet) [NCBI Gene 5214] {aka ATP-PFK, PFK-C, PFK-P, PFKF}, KAT7 (lysine acetyltransferase 7) [NCBI Gene 11143] {aka HBO1, HBOA, MYST2, ZC2HC7}, CCR4 (C-C motif chemokine receptor 4) [NCBI Gene 1233] {aka CC-CKR-4, CD194, CKR4, CMKBR4, ChemR13, HGCN:14099}, HCAR1 (hydroxycarboxylic acid receptor 1) [NCBI Gene 27198] {aka FKSG80, GPR104, GPR81, HCA1, LACR1, TA-GPCR}, EEF1A2 (eukaryotic translation elongation factor 1 alpha 2) [NCBI Gene 1917] {aka DEE33, EEF1AL, EF-1-alpha-2, EF1A, EIEE33, HS1}, USP39 (ubiquitin specific peptidase 39) [NCBI Gene 10713] {aka 65K, CGI-21, HSPC332, SAD1, SNRNP65}, TTK (TTK protein kinase) [NCBI Gene 7272] {aka CT96, ESK, MPH1, MPS1, MPS1L1, PYT}, PFKL (phosphofructokinase, liver type) [NCBI Gene 5211] {aka ATP-PFK, PFK-B, PFK-L}, PDK1 (pyruvate dehydrogenase kinase 1) [NCBI Gene 5163], IL10 (interleukin 10) [NCBI Gene 3586] {aka CSIF, GVHDS, IL-10, IL10A, TGIF}, PCK2 (phosphoenolpyruvate carboxykinase 2, mitochondrial) [NCBI Gene 5106] {aka PEPCK, PEPCK-M, PEPCK2, mtPCK2}, KCNK1 (potassium two pore domain channel subfamily K member 1) [NCBI Gene 3775] {aka DPK, HOHO, K2P1, K2p1.1, KCNO1, TWIK-1}, HK1 (hexokinase 1) [NCBI Gene 3098] {aka CNSHA5, HK, HK1-ta, HK1-tb, HK1-tc, HKD}, KIAA0753 (KIAA0753) [NCBI Gene 9851] {aka JBTS38, MNR, OFIP, SRTD21}, SLC2A3 (solute carrier family 2 member 3) [NCBI Gene 6515] {aka GLUT3}, METTL16 (methyltransferase 16, RNA N6-adenosine) [NCBI Gene 79066] {aka METT10D}, CEACAM6 (CEA cell adhesion molecule 6) [NCBI Gene 4680] {aka CD66c, CEAL, NCA, NCA-50/90}, LDHA (lactate dehydrogenase A) [NCBI Gene 3939] {aka GSD11, HEL-S-133P, LDHM, PIG19}, ALDH1A3 (aldehyde dehydrogenase 1 family member A3) [NCBI Gene 220] {aka ALDH1A6, ALDH6, MCOP8, RALDH3}, SIRT2 (sirtuin 2) [NCBI Gene 22933] {aka SIR2, SIR2L, SIR2L2}, EIF2AK3 (eukaryotic translation initiation factor 2 alpha kinase 3) [NCBI Gene 9451] {aka PEK, PERK, WRS}, SPATA2 (spermatogenesis associated 2) [NCBI Gene 9825] {aka PD1, PPP1R145, tamo}, KAT2A (lysine acetyltransferase 2A) [NCBI Gene 2648] {aka GCN5, GCN5L2, PCAF-b, hGCN5}, ABCF1 (ATP binding cassette subfamily F member 1) [NCBI Gene 23] {aka ABC27, ABC50}, METTL5 (methyltransferase 5, N6-adenosine) [NCBI Gene 29081] {aka HSPC133, MRT72}, PACERR (PTGS2 antisense NFKB1 complex-mediated expression regulator RNA) [NCBI Gene 103752588] {aka PACER, PTGS2-AS1, PTGS2AS1}, AKT1 (AKT serine/threonine kinase 1) [NCBI Gene 207] {aka AKT, PKB, PKB-ALPHA, PRKBA, RAC, RAC-ALPHA}, ACO1 (aconitase 1) [NCBI Gene 48] {aka ACONS, HEL60, IREB1, IREBP, IREBP1, IRP1}, PGAM1 (phosphoglycerate mutase 1) [NCBI Gene 5223] {aka HEL-S-35, PGAM-B, PGAMA}, CEMIP (cell migration inducing hyaluronidase 1) [NCBI Gene 57214] {aka CCSP1, CEMIP1, HYBID, KIAA1199, TMEM2L}, H4C6 (H4 clustered histone 6) [NCBI Gene 8361] {aka H4, H4/c, H4FC, HIST1H4F}, NBN (nibrin) [NCBI Gene 4683] {aka AT-V1, AT-V2, ATV, NBS, NBS1, P95}, SEMA3A (semaphorin 3A) [NCBI Gene 10371] {aka COLL1, HH16, Hsema-I, Hsema-III, SEMA1, SEMAD}, PARP1 (poly(ADP-ribose) polymerase 1) [NCBI Gene 142] {aka ADPRT, ADPRT 1, ADPRT1, ARTD1, PARP, PARP-1}, DPF2 (double PHD fingers 2) [NCBI Gene 5977] {aka CSS7, REQ, SMARCG2, UBID4, ubi-d4}, XRCC1 (X-ray repair cross complementing 1) [NCBI Gene 7515] {aka RCC, SCAR26}, H19 (H19 imprinted maternally expressed transcript) [NCBI Gene 283120] {aka ASM, ASM1, BWS, D11S813E, GMRSP, LINC00008}
- **Diseases:** osteoporosis (MESH:D010024), liver fibrosis (MESH:D008103), Tumour (MESH:D009369), resistance (MESH:D060467), Huntington's disease (MESH:D006816), diabetic (MESH:D003920), cardiovascular disease (MESH:D002318), idiopathic pulmonary fibrosis (MESH:D054990), myocardial infarction (MESH:D009203), Alzheimer's disease (MESH:D000544), pancreatic cancer (MESH:D010190), CRC (MESH:D015179), Parkinson's disease (MESH:D010300), cervical cancer (MESH:D002583), endometrial cancer (MESH:D016889), metastasis (MESH:D009362), gliomas (MESH:D005910), melanoma (MESH:D008545), fibrosis (MESH:D005355), epilepsy (MESH:D004827), prostate cancer (MESH:D011471), Inflammatory (MESH:D007249), LACTATE (MESH:D007775), arterial calcification (MESH:D061205), neurodegenerative and metabolic diseases (MESH:D019636), PDAC (MESH:D021441), MPE (MESH:D016066), ccRCC (MESH:D002292), NSCLC (MESH:D002289), GBM (MESH:D005909), lung squamous cell carcinoma (MESH:D002294), neuroblastoma (MESH:D009447), metabolic abnormalities (MESH:D008659), HCC (MESH:D006528), ovarian cancer (MESH:D010051), liver carcinogenesis (MESH:D063646), triple-negative breast cancer (MESH:D064726), kidney fibrosis (MESH:D007674), breast cancer (MESH:D001943), hypoxic (MESH:D002534), gastric cancer (MESH:D013274)
- **Chemicals:** pentose phosphate (MESH:D010428), GAP (MESH:D005986), S-D-lactoylglutathione (MESH:C013585), 2-DG (MESH:D003847), TMZ (MESH:D000077204), glucose-6-phosphate (MESH:D019298), Lactate (MESH:D019344), AZD3965 (MESH:C000592351), N1-methyladenosine (MESH:C002230), oxygen (MESH:D010100), 1,3-bisphosphoglycerate (MESH:C015891), fructose-1,6-bisphosphate (MESH:C029063), fructose-6-phosphate (MESH:C027618), platinum (MESH:D010984), Pyruvate (MESH:D019289), D34 (-), bevacizumab (MESH:D000068258), 2-PG (MESH:C008885), glucose (MESH:D005947), DHAP (MESH:D004099), NADH (MESH:D009243), lysine (MESH:D008239), lenvatinib (MESH:C531958), iron (MESH:D007501), 3-PG (MESH:C005156), lipid (MESH:D008055), PEP (MESH:D010728), stiripentol (MESH:C021092), ATP (MESH:D000255), water (MESH:D014867), lactyl-CoA (MESH:C047009), Tanshinone I (MESH:C021751), L (MESH:D007930)
- **Species:** Homo sapiens (human, species) [taxon 9606]
- **Cell lines:** HEK293T — Homo sapiens (Human), Transformed cell line (CVCL_0063), HeLa — Homo sapiens (Human), Human papillomavirus-related endocervical adenocarcinoma, Cancer cell line (CVCL_0030)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12914357/full.md

## Figures

5 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12914357/full.md

## References

239 references — full list in the complete paper: https://tomesphere.com/paper/PMC12914357/full.md

---
Source: https://tomesphere.com/paper/PMC12914357